

REMARKS


The specification has been amended to incorporate the Sequence Listing filed herewith and to add an incorporation-by-reference statement regarding the Sequence Listing. Relative to the Sequence Listing previously on file in the application, the Sequence Listing filed herewith includes SEQ ID NOS:300 and 301, the sequences recited in claims 168 and 169. The header information in fields <110>-<170> has also been updated.

Claims 168-171 have been amended. Claims 168 and 169 have been amended to refer to SEQ ID NOS:300 and 301, respectively. Claims 170 and 171 have been amended to delete references to sequence identifiers. These sequences of claims 170 and 171 contain D-amino acids and are thus not considered "amino acid sequences" for the purposes of the Sequence Listing requirements, per 37 C.F.R. § 1.821(a)(2).

No new matter has been added by the present amendment. If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: February 25, 2010



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045